Y's AC

Y's AC is a Japanese biotechnology company focused on developing innovative therapeutic agents for cancer and immune disorders, primarily targeting the CD26 molecule. The company's lead asset, YS110, is a humanized monoclonal antibody that has shown promising safety and efficacy in clinical trials for malignant mesothelioma and other CD26-expressing solid tumors. Spun off from Y's Therapeutics in 2010, Y's AC collaborates with academic institutions like the University of Tokyo and has a strategic partnership with Kissei Pharmaceutical for the development and commercialization of YS110 in Japan. The company also explores the potential of CD26-targeted therapies in treating viral infections such as MERS-CoV and various immune-related conditions.